顶部联系方式

Time of issue:2018-03-12 00:00:00

Have Any Questions?  Mabspace BiosciencesInfo@mabspacebio.com 迈博斯生物0512-86861701

搜索
迈博斯生物

语言切换

Time of issue:2019-11-21 00:00:00
这是描述信息

NEWS

>>
Industrial News
Transcenta Holding Announces Licensing Agreement with Lilly
Transcenta Holding Announces Licensing Agreement with Lilly
Hong Kong, Suzhou, Hangzhou, China - March 29th, 2019 – Transcenta Holding (Transcenta) today announces that its wholly-owned subsidiary, HJB, has signed an exclusive agreement with Eli Lilly and Company (Lilly) to license a portfolio of novel biotherapeutics programs in the therapeutic area of bone diseases for development and commercialization in Greater China,
See more information
Hong Kong, Suzhou, Hangzhou, China - March 29th, 2019 – Transcenta Holding (Transcenta) today announces that its wholly-owned subsidiary, HJB, has signed an exclusive agreement with Eli Lilly and Company (Lilly) to license a portfolio of novel biotherapeutics programs in the therapeutic area of bone diseases for development and commercialization in Greater China, 
Transcenta Holding announces appointment of Dr. Yi Gu as Senior Vice President and Head of Research
Transcenta Holding announces appointment of Dr. Yi Gu as Senior Vice President and Head of Research
Suzhou, China – March 11, 2019 – Transcenta Holding(Transcenta), an innovative biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing, announced today the appointment of Dr. Yi Gu as its Senior Vice President and Head of Research.
See more information
Suzhou, China – March 11, 2019 – Transcenta Holding(Transcenta), an innovative biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing, announced today the appointment of Dr. Yi Gu as its Senior Vice President and Head of Research. 
HJB Merges with MabSpace Biosciences to Form Transcenta Holding, a Fully Integrated Leading Global Biotherapeutics Company
HJB Merges with MabSpace Biosciences to Form Transcenta Holding, a Fully Integrated Leading Global Biotherapeutics Company
HONG KONG, SHANGHAI, SUZHOU and HANGZHOU, China, Jan. 1, 2019 -- HJB and MabSpace Biosciences (MabSpace) today announced that the two companies have entered into a definitive merger agreement to create Transcenta Holding Ltd. (Transcenta), a world-class biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics. Dr. Xueming Qian, former Founder, Chairman and CEO of
See more information
HONG KONG, SHANGHAI, SUZHOU and HANGZHOU, China, Jan. 1, 2019 -- HJB and MabSpace Biosciences (MabSpace) today announced that the two companies have entered into a definitive merger agreement to create Transcenta Holding Ltd. (Transcenta), a world-class biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics. Dr. Xueming Qian, former Founder, Chairman and CEO of 
MabSpace Biosciences Doses First Patient in China Phase 1 Trial for MSB2311 and Submitted IND for MSB0254 to NMPA
MabSpace Biosciences Doses First Patient in China Phase 1 Trial for MSB2311 and Submitted IND for MSB0254 to NMPA
SUZHOU, China--(BUSINESS WIRE)--MabSpace Biosciences announced that on August 24th, 2018, MSB2311 was successfully administered to the first Chinese cancer patient at Beijing Cancer Hospital in its China Phase 1 trial. MSB2311 is a 2nd-generation PD-L1 antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumor penetration.
See more information
SUZHOU, China--(BUSINESS WIRE)--MabSpace Biosciences announced that on August 24th, 2018, MSB2311 was successfully administered to the first Chinese cancer patient at Beijing Cancer Hospital in its China Phase 1 trial. MSB2311 is a 2nd-generation PD-L1 antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumor penetration.
Full seat of Village B | Qianbo Ming, CEO of Maibos Bio: Looking for the next PD-1 (L1) "Go Back to Science"
Full seat of Village B | Qianbo Ming, CEO of Maibos Bio: Looking for the next PD-1 (L1) "Go Back to Science"
From doctors in neurobiology at Columbia University and Albany Medical College to postdoctoral and chief scientists at Amgen, ...
See more information
From doctors in neurobiology at Columbia University and Albany Medical College to postdoctoral and chief scientists at Amgen, ...
Previous page
1
2
5

页脚关于我们

Time of issue:2019-11-23 00:00:00

页脚管道

Time of issue:2019-11-23 00:00:00

页脚新闻

Time of issue:2019-11-23 00:00:00

页脚人力资源

Time of issue:2019-11-23 00:00:00

页脚联系方式

Time of issue:2019-11-23 00:00:00

页脚版权

Time of issue:2019-11-23 00:00:00

Copyright © 2019 Mabspace Biosciences All rights reserved

页脚备案

Time of issue:2019-11-23 00:00:00